LANSING, Mich., August 4 — ACT LAB, a multistate cannabis and hemp testing and compliance laboratory network with more than 12 years in the cannabis testing space, announced its expansion into New Jersey. The move further advances the company’s strategy to deliver the consistent results, operational excellence, and responsive customer support that regulated cannabis businesses depend on. The expansion follows the acquisition of Sriven Labs (SV Labs – NJ), a licensed cannabis testing laboratory serving New Jersey’s regulated cannabis market.
New Jersey represents an important milestone in ACT LAB’s continued growth. As one of the nation’s fastest-growing regulated cannabis markets, the state provides a significant opportunity to bring ACT LAB’s best-in-class turnaround times and superior customer service to support operators, protect consumers, and strengthen confidence in regulated cannabis products.
“ACT LAB’s expansion in New Jersey builds on the strong customer relationships, local knowledge, and experienced team established by Sriven Labs, while adding the scientific depth and resources of one of the nation’s largest and most experienced cannabis testing laboratory networks,” said J. Michael Drozd, CEO of ACT LAB. “In addition to strengthening local testing capabilities, ACT LAB’s national laboratory network provides meaningful value for both multistate operators and independent cannabis businesses who operate in New Jersey.”
ACT LAB offers customers access to 100+ years of collective cannabis testing expertise, standardized analytical methods, and robust quality systems designed to deliver consistent, reliable results. The company’s growing national footprint and harmonized testing methodologies protect brand integrity by providing greater consistency across markets. ACT LAB’s customer data portal delivers centralized access to multistate testing data and provides trending tools to give customers the information they need to make faster, more informed business decisions.
“As regulated cannabis markets continue to mature, high-quality and consistent laboratory services are increasingly important to helping operators reduce risk, improve consistency, and make better business decisions,” said Austin Stevenson, Chief Revenue Officer at ACT LAB. “Our investment in New Jersey reflects ACT LAB’s commitment to being a long-term testing and compliance partner that supports operational excellence and delivers the resources operators need to succeed.”
The New Jersey expansion builds on ACT LAB’s continued investment in laboratory infrastructure across the United States. Over the past year, the company expanded its Pennsylvania operations with a second laboratory in Harrisburg, relocated and expanded its Ohio laboratory to Columbus to improve statewide service and turnaround times, and completed an expansion of its Illinois laboratory to increase testing capacity for operators. Together, these investments reflect ACT LAB’s long-term strategy of building standardized laboratory operations that deliver consistent results across multiple markets.
“New Jersey’s regulated cannabis market is poised for continued growth,” said Drozd. “We appreciate the New Jersey Cannabis Regulatory Commission’s approval of this acquisition and look forward to partnering with both our customers and the CRC to give businesses and consumers confidence in the products on the dispensary shelf.”
Customers will continue working through their existing local contacts, while gaining access to ACT LAB’s broader scientific resources, standardized methodologies, and multistate laboratory network. The company remains committed to maintaining continuity of service while investing in additional laboratory capabilities that support New Jersey’s regulated cannabis industry.